Evidence map›Paper›PMID 37342987›Full record

SynthesisClinical pharmacology and therapeutics2023

Prognostic Factors of COVID-19: An Umbrella Review Endorsed by the International Society for Pharmacoepidemiology.

Grammati Sarri, Wei Liu, Luke Zabotka, Andreas Freitag, Ravinder Claire, Grace Wangge, Jamie Elvidge, Dalia Dawoud, Dimitri Bennett, Xuerong Wen and 11 more

Open access · hybridAbstract readSystematic Review
In one paragraph

Synthesis in Clinical pharmacology and therapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 17 institutions in 7 countries.

Grammati SarriCytel, London, UK.ORCID 0000-0001-5536-8038
Wei LiuOffice of Surveillance and Epidemiology, CDER, US Food and Drug Administration, Silver Spring, Maryland, USA.ORCID 0000-0002-0434-4674
Luke ZabotkaBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Andreas FreitagCytel, London, UK.ORCID 0000-0003-0265-9338
Ravinder ClaireNational Institute for Health and Care Excellence, London, UK.ORCID 0000-0001-8039-6161
Grace WanggeMonash University, Banten, Indonesia.
Jamie ElvidgeNational Institute for Health and Care Excellence, London, UK.
Dalia DawoudNational Institute for Health and Care Excellence, London, UK.ORCID 0000-0002-2105-1937
Dimitri BennettTakeda Development Center Americas, Inc., Cambridge, Massachusetts, USA.ORCID 0000-0002-8387-9342
Xuerong WenCollege of Pharmacy, University of Rhode Island, Kingston, Rhode Island, USA.ORCID 0000-0002-4803-7895
Xiaojuan LiDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts, USA.
Christopher T RentschFaculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, London, UK.ORCID 0000-0002-1408-7907
Md Jamal UddinDepartment of Statistics, Shahjalal University of Science and Technology, Sylhet, Bangladesh.
M Sanni AliFaculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, London, UK.
Mugdha GokhalePfizer Inc., New York, New York, USA.
Anouk Déruaz-LuyetBoehringer Ingelheim International GmbH, Ingelheim-am-Rhein, Germany.ORCID 0000-0001-7396-7392
Daniela C MogaDepartment of Pharmacy Practice and Science, College of Pharmacy, University of Kentucky, Lexington, Kentucky, USA.ORCID 0000-0002-3648-8197
Jeff Jianfei GuoDivision of Pharmacy Practice & Administrative Sciences, College of Pharmacy, University of Cincinnati, Cincinnati, Ohio, USA.
Andrew R ZulloDepartment of Epidemiology, School of Public Health, Brown University, Providence, Rhode Island, USA.ORCID 0000-0003-1673-4570
Elisabetta PatornoBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Kueiyu Joshua LinBrigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Brigham and Women's Hospital · USCytel (United States) · USNational Institute for Health and Care Excellence · GBBoehringer Ingelheim (Germany) · DEBrown University · USCairo University · EGHarvard University · USLiverpool School of Tropical Medicine · GBMonash University Malaysia · MYPfizer (United States) · USShahjalal University of Science and Technology · BDTakeda (United States) · USUnited States Food and Drug Administration · USUniversity of Cincinnati · USUniversity of Kentucky · USUniversity of London · GBUniversity of Rhode Island · US

Funding

Clinically Significant Drug Interactions among Nursing Home Residents with ADRDR01AG077620 · NIA · BROWN UNIVERSITY · PI Andrew Reis Zullo · 2022 to 2026
$3.5M
Medications and the Risk of Motor Vehicle Crashes in Older AdultsR01AG065722 · NIA · BROWN UNIVERSITY · PI ZULLO, ANDREW REIS · 2020 to 2023
$2.1M
Research Continuity and Retention Supplement: Optimizing care for older adults in the new treatment era for type 2 diabetes and heart failureK01AG073651 · NIA · HARVARD PILGRIM HEALTH CARE, INC. · PI Xiaojuan Li · 2022 to 2026
$700k
Opioid use in post-acute hip fracture care: prescribing patterns, effectiveness, and safetyR21AG061632 · NIA · BROWN UNIVERSITY · PI BEAUDOIN, FRANCESCA, ZULLO, ANDREW REIS · 2019 to 2020
$462k
Novel causal inference methods to inform clinical decision on when to discontinue symptomatic treatment for patients with dementiaR03AG070661 · NIA · HARVARD PILGRIM HEALTH CARE, INC. · PI LI, XIAOJUAN · 2021 to 2022
$332k
FDA HHS U01 FD007213NIA NIH HHS K01 AG073651NIA NIH HHS R01 AG065722NIA NIH HHS R01 AG077620NIA NIH HHS R03 AG070661NIA NIH HHS R21 AG061632
6 · The paper itself

Abstract

During the coronavirus disease 2019 (COVID-19) pandemic, the urgency for updated evidence to inform public health and clinical care placed systematic literature reviews (SLRs) at the cornerstone of research. We aimed to summarize evidence on prognostic factors for COVID-19 outcomes through published SLRs and to critically assess quality elements in the findings' interpretation. An umbrella review was conducted via electronic databases from January 2020 to April 2022. All SLRs (and meta-analyses) in English were considered. Data screening and extraction were conducted by two independent reviewers. AMSTAR 2 tool was used to assess SLR quality. The study was registered with PROSPERO (CRD4202232576). Out of 4,564 publications, 171 SLRs were included of which 3 were umbrella reviews. Our primary analysis included 35 SLRs published in 2022, which incorporated studies since the beginning of the pandemic. Consistent findings showed that, for adults, older age, obesity, heart disease, diabetes, and cancer were more strongly predictive of risk of hospitalization, intensive care unit admission, and mortality due to COVID-19. Male sex was associated with higher risk of short-term adverse outcomes, but female sex was associated with higher risk of long COVID. For children, socioeconomic determinants that may unravel COVID-19 disparities were rarely reported. This review highlights key prognostic factors of COVID-19, which can help clinicians and health officers identify high-risk groups for optimal care. Findings can also help optimize confounding adjustment and patient phenotyping in comparative effectiveness research. A living SLR approach may facilitate dissemination of new findings. This paper is endorsed by the International Society for Pharmacoepidemiology.

Indexed as

COVID-19AdultChildFemaleHospitalizationHumansMalePharmacoepidemiologyPost-Acute COVID-19 SyndromePrognosis

Identifiers

PMID37342987
PMCPMC12024729
OpenAlexW4381597452

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.